| Name | Title | Contact Details |
|---|
JK Associates is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iMedicor, Inc. is a national provider of comprehensive secure communications solutions for the medical and dental communities. iMedicor offers dentists, general practitioners, specialized doctors and other healthcare professionals the use of a secure, HIPAA-compliant communications network that addresses current federal standards for security and interoperability. iMedicor also serves as one of the country's leading Meaningful Use consultants to assist doctors and dentists with conversion from paper to electronic health records (EHRs) and qualify under Medicare and Medicaid guidelines for Federal Incentive Funding.
HealthPRO Rehabilitation Management Services is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cockeysville, MD. To find more information about HealthPRO Rehabilitation Management Services, please visit www.healthpro-rehab.com
In 1969, AvMed began in South Florida as Aviation Medicine to serve the growing airline industry by providing pilot physicals. Today, with offices in every major metropolitan area of the state, AvMed aims to inspire its membership of 300,000 Floridians to “Embrace better health.” AvMed provides Medicare Advantage coverage in Broward and Miami-Dade counties, Individual and Family coverage in Broward, Miami-Dade, and Palm Beach counties and Commercial coverage in more than 30 counties across the state. Major employer clients have been partners for decades, a testament to AvMed`s culture of service, which consistenly ranks above statewide peers.
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.